NCT05255601

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.

Conditions

• Lymphoma, Non-Hodgkin
• Hodgkin Disease

Interventions

Type	Name	Description
DRUG	Relatlimab	Specified Dose on Specified Days
DRUG	Nivolumab	Specified Dose on Specified Days

Timeline

• Start date: 2022-09-13
• Primary completion: 2025-12-03
• Completion: 2025-12-03
• First posted: 2022-02-24
• Last updated: 2026-02-25

Locations

51 sites across 7 countries: United States, Australia, France, Italy, Netherlands, Spain, United Kingdom

Regulatory

• FDA-regulated drug study